P
Pascale A. Cohen
Researcher at Claude Bernard University Lyon 1
Publications - 38
Citations - 2047
Pascale A. Cohen is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 22, co-authored 36 publications receiving 1839 citations. Previous affiliations of Pascale A. Cohen include French Institute of Health and Medical Research & University of Lyon.
Papers
More filters
Journal ArticleDOI
Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors
Muriel Le Romancer,Coralie Poulard,Pascale A. Cohen,Stéphanie Sentis,Jack-Michel Renoir,Jack-Michel Renoir,Laura Corbo +6 more
TL;DR: A thorough understanding of the complete picture of these modifications in ER carcinogenesis might not only open new avenues for identifying new markers for prognosis or prediction of response to endocrine therapy but also could promote the development of novel therapeutic strategies.
Journal ArticleDOI
Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach
Sengül Tozlu,Igor Girault,Sophie Vacher,Julie A. Vendrell,Catherine Andrieu,F. Spyratos,Pascale A. Cohen,Rosette Lidereau,Ivan Bièche +8 more
TL;DR: Surprisingly, only a small proportion of the 51 genes identified in breast tumor biopsy specimens were confirmed to be ERalpha-regulated and/or E2-regulated in vitro (cultured cell lines) and better delineate the role of ERalpha in breast cancer.
Journal ArticleDOI
Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
TL;DR: This review provides an overview of the most recent patents, of pre-clinical and clinical studies of inhibitors targeting the different members and/or activators of the PI3K/Akt/mTOR pathway, used alone or in combination with other targeted agents for the treatment of breast cancer.
Journal ArticleDOI
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Sandra E. Ghayad,Julie A. Vendrell,Sabrina Ben Larbi,Charles Dumontet,Ivan Bièche,Pascale A. Cohen +5 more
TL;DR: In conclusion, the combination of MAPK and PI3K inhibitors represents a promising strategy to overcome endocrine therapy resistance in ER+ breast cancer patients.
Journal ArticleDOI
ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion.
Julie A. Vendrell,Aurélie Thollet,Nhan Trung Nguyen,Sandra E. Ghayad,Stéphanie Vinot,Ivan Bièche,Evelyne Grisard,Véronique Josserand,Jean-Luc Coll,Pierre Roux,Laura Corbo,Isabelle Treilleux,Ruth Rimokh,Pascale A. Cohen +13 more
TL;DR: Findings indicate that ZNF217 mRNA expression may represent a novel prognostic biomarker in breast cancer and therapeutic targeting of Z NF217 of the TGF-β signaling pathway may benefit the subset of patients whose tumors express high levels of ZNF 217.